Investigational drugs in recent clinical trials for treatment-resistant depression.

ABSTRACT:

Introduction

The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for other, more selective glutamatergi

SUBMITTER: Garay RP 

PROVIDER: S-EPMC5418088 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature